2609 — Bayzed Health Income Statement
0.000.00%
Last trade - 00:00- HK$8.12bn
- HK$8.69bn
- CNY1.19bn
Annual income statement for Bayzed Health, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 803 | 1,072 | 1,189 |
| Cost of Revenue | |||
| Gross Profit | 79.6 | 178 | 208 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 841 | 1,050 | 1,154 |
| Operating Profit | -38.1 | 22.4 | 35 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -62.5 | -4.61 | 13.3 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -75.5 | -24.4 | -3.56 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -58 | -26.4 | -13.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -58 | -26.4 | -13.5 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.044 | -0.027 | -0.018 |